- Home
- NVS
NVS
Novartis AG
as 10-30-2025 9:32am EST
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 254.8B | IPO Year: | 1991 |
| Target Price: | $119.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 7.30 | EPS Growth: | -14.91 |
| 52 Week Low/High: | $96.06 - $133.55 | Next Earning Date: | 10-28-2025 |
| Revenue: | $56,372,000,000 | Revenue Growth: | 12.88% |
| Revenue Growth (this year): | 9.06% | Revenue Growth (next year): | 2.54% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Novartis Says Ianalumab Showed Reduced Disease Activity in Phase III Trials for Sjogren's Disease
GlobeNewswire
a day ago
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
Zacks
a day ago
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Zacks
a day ago
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
Morningstar Research
a day ago
Analyst Report: Novartis AG
PR Newswire
2 days ago
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
Investor's Business Daily
2 days ago
Novartis Slips As Generics Bite Into Its Heart-Failure Drug Sales In Mixed Third Quarter
GuruFocus.com
2 days ago
Novartis Profit Rises on Cancer Drug Momentum
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.